Most people taking omega-3 supplements are not getting the dose the evidence supports. Not even close.

The label on your fish oil capsule says 1000mg. The studies that showed significant reductions in cardiovascular mortality, heart attacks, and cognitive decline used 2,000 to 4,000mg of the active molecules, EPA and DHA, per day. A standard 1000mg fish oil capsule delivers approximately 300mg of combined EPA and DHA. The rest is other fats your body does not need more of.

That gap, between what the label implies and what the evidence actually requires, is where most fish oil supplements live. And the dose problem is only part of it. Most supplements are in a form that absorbs poorly. Most have oxidized before you open the bottle. And most people have no idea any of this is happening because nothing on the label tells them.

The omega-3 evidence is among the strongest in nutritional supplementation. The standard fish oil routine is not delivering it.

Let’s run it through the filter.

Fish oil is the delivery vehicle. It is the oil extracted from fatty fish. It contains EPA and DHA but also other fatty acids that are not the active molecules behind the evidence.
EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) are the active molecules. Every major clinical trial that showed cardiovascular, cognitive, and metabolic benefit dosed on EPA and DHA specifically, not total fish oil weight.

This distinction matters because the supplement industry built its entire marketing around total fish oil milligrams, not active EPA+DHA content. A bottle labeled “1000mg Omega-3 Fish Oil” typically contains 300mg of combined EPA+DHA. The remaining 700mg is other fatty acids. The label is not lying, it is simply measuring the wrong thing.

The one number that matters is the combined EPA+DHA total, listed separately in the Supplement Facts panel. If that number is below 500mg per serving, the product is unlikely to produce the outcomes the evidence supports. If the Supplement Facts panel does not list EPA and DHA separately, that is itself a quality signal.

The average American consumes approximately 100mg of combined EPA and DHA per day from diet alone, roughly one-tenth of the 1,000mg the American Heart Association recommends for cardiovascular support, and one-twentieth of the doses used in the strongest cardiovascular trials. This gap widens after 40 for two compounding reasons.

First, the ratio of omega-6 to omega-3 fatty acids in the typical Western diet has shifted dramatically toward omega-6 over the past 50 years, driven by processed food and seed oils. This imbalance promotes a chronic low-grade inflammatory state that EPA and DHA directly counteract.

Second, cardiovascular risk accumulates with age, and the evidence for EPA and DHA is strongest in populations where that risk is highest.

The omega-3 index, the percentage of EPA and DHA in red blood cell membranes, is the biomarker that most reliably predicts cardiovascular and cognitive outcomes. An omega-3 index of 8% or higher is associated with the lowest risk of cardiovascular events, stroke, and all-cause mortality. The average American has an omega-3 index of approximately 5.5%. Achieving 8% requires roughly 1,000mg additional EPA+DHA per day beyond typical dietary intake, which means supplementation is not optional for most people over 40 who do not eat fatty fish multiple times per week.

Yes. The evidence base is among the strongest in nutritional supplementation across multiple outcome domains.

CARDIOVASCULAR MORTALITY AND EVENTS: Strong, consistent evidence. A 2025 meta-analysis published in Clinical and Translational Discovery analyzed 42 studies involving 176,253 participants. Omega-3 supplementation significantly reduced cardiovascular mortality, cardiovascular disease, coronary heart disease, myocardial infarction, fatal myocardial infarction, and revascularization. The effect was dose-dependent, higher EPA+DHA doses produced greater cardiovascular risk reduction. This is one of the largest and most comprehensive meta-analyses of omega-3 cardiovascular outcomes ever conducted.

COGNITIVE FUNCTION: Real, dose-dependent evidence. A 2025 dose-response meta-analysis of 58 RCTs found that each 2,000mg per day increment in omega-3 supplementation produced significant improvements in attention, perceptual speed, language, and primary memory in adults. DHA is the dominant structural fatty acid in the brain, it comprises approximately 97% of all omega-3 fatty acids in brain tissue, and higher omega-3 blood levels are associated with better preservation of white matter integrity and reduced hippocampal atrophy with aging.

TRIGLYCERIDES: Most consistent finding in the literature. The American Heart Association confirmed that 2-4g per day of EPA+DHA reduces triglycerides by 20-30% in individuals with elevated levels. The FDA has approved prescription omega-3 formulations specifically for hypertriglyceridemia based on this evidence. The triglyceride reduction is confirmed across dozens of RCTs and is the most replicated cardiovascular finding in the entire omega-3 literature. It requires therapeutic dosing, not 300mg from a standard capsule.

INFLAMMATION: Consistent mechanistic and clinical evidence. EPA and DHA are precursors to anti-inflammatory eicosanoids and resolvins. They directly suppress the production of pro-inflammatory cytokines via NF-kB pathway inhibition. Clinical evidence confirms reductions in CRP, IL-6, and TNF-alpha at therapeutic doses. The anti-inflammatory effect is particularly relevant for the 40-70 demographic where chronic low-grade inflammation is a primary driver of cardiovascular disease, cognitive decline, and metabolic dysfunction.

The dose gap is the first problem. The form and quality of most supplements is the second.

The absorption problem:

Not all omega-3 forms absorb equally. The most common and cheapest form, ethyl ester, has significantly lower bioavailability than triglyceride form. Research shows that omega-3 in triglyceride form is absorbed up to 71% more efficiently than ethyl ester form. Ethyl ester requires enzymatic conversion before absorption, and without a fatty meal this conversion is inefficient, one study found only 20% of ethyl ester omega-3 absorbed in a fasted state vs. 60% with a high-fat meal. Triglyceride form absorbs substantially better in both conditions.

How to identify the form: look for “rTG” or “re-esterified triglyceride” on the label. “EE” means ethyl ester. Most cheap fish oil products are ethyl ester. Many do not state the form at all, which is itself a quality signal.

The oxidation problem:

Omega-3 fatty acids are highly susceptible to oxidation. Rancid fish oil does not just lose effectiveness, oxidized omega-3s may actively increase inflammatory markers rather than reduce them. Multiple independent analyses have found that over 80% of commercial fish oil products exceed recommended oxidation limits set by the Global Organisation for EPA and DHA Omega-3s (GOED).

How to test your current supplement: cut or pierce a capsule and smell it. Fresh fish oil has a mild, clean smell. Rancid oil smells strongly fishy, sour, or paint-like. If it fails the smell test, discard it.

The dose per capsule problem:

Standard fish oil capsules typically deliver 300mg combined EPA+DHA per capsule. To reach a therapeutic dose of 2,000mg EPA+DHA, you would need 6-7 standard capsules per day. This is why high-quality concentrated supplements that deliver 750-1250mg EPA+DHA per capsule are worth the premium, they make therapeutic dosing practical.

The atrial fibrillation signal has been widely reported and requires honest disclosure. Prior meta-analyses found increased AF risk with omega-3 supplementation. However, a comprehensive December 2025 meta-analysis of 34 RCTs and 114,326 participants, the largest ever conducted on this question, found a critical nuance: the AF risk increase was statistically significant only in people at high cardiovascular risk who were taking high pharmacological doses (above 1,500mg/day from prescription formulations). In people at low cardiovascular risk taking standard supplemental doses, there was no statistically significant increase in AF risk. For otherwise healthy adults supplementing at 1,000-2,000mg EPA+DHA per day, the current evidence does not support a meaningful AF risk increase.

The evidence is also stronger in populations with elevated cardiovascular risk or established deficiency than in healthy, well-nourished populations. If you eat fatty fish three or more times per week, your baseline omega-3 status may already be adequate and the incremental benefit of supplementation is smaller.

ALA from plant sources, flaxseed, chia seeds, walnuts, does not substitute for marine EPA and DHA. The human body converts less than 5% of ALA to EPA and less than 1% to DHA. Plant-based omega-3 sources do not produce the cardiovascular or cognitive outcomes the evidence supports. Marine sources only.

The MED Report position: the evidence is strongest at therapeutic doses (1,000-2,000mg EPA+DHA/day) from a quality source in triglyceride form. The standard 300mg capsule routine is not it.

A high-quality triglyceride-form fish oil delivering 1,000-2,000mg EPA+DHA per day costs approximately $30-50 per month. That is significantly more than the $10-15 bottles of underdosed ethyl ester oil most people are buying.

The question is whether the evidence justifies the premium. For the 40-70 demographic with suboptimal dietary omega-3 intake, which is most Americans, the cardiovascular, cognitive, and metabolic evidence at therapeutic doses is consistent and clinically meaningful. The triglyceride reduction alone is worth the investment for anyone with elevated triglycerides.

For comparison: the average American over 50 spends over $100 per month on supplements, most of which have a fraction of the evidence base that therapeutic-dose EPA+DHA has. Spending $30-50 on something with a 176,000-participant cardiovascular meta-analysis behind it is a defensible ROI decision.

The cheap version, however, is not worth it. An underdosed, ethyl ester, potentially oxidized fish oil capsule is not delivering the outcomes the evidence supports. In that specific case, save your money or spend the premium on a product that actually works.

Two important disclosures for specific populations:

The fish oil industry has built a multi-billion dollar market on selling you the idea of omega-3s while quietly delivering a fraction of the therapeutic dose in a form that absorbs poorly and often oxidizes before you open the bottle.

The labeling is technically accurate. “1000mg Omega-3 Fish Oil” is true. It just does not tell you that the active molecules in that 1000mg add up to 300mg, that the form those molecules are in absorbs 71% less efficiently than the alternative, or that the product may have exceeded its oxidation limit before it arrived on your doorstep.

The system rewards cheap production, high-margin labeling, and consumer confusion. The evidence rewards none of it.

That gap is exactly what this newsletter exists to close.

How to evaluate your current supplement:

One note on ALA:

Flaxseed oil, chia seed oil, and other plant omega-3 supplements are ALA, not EPA or DHA. The human body converts less than 5% of ALA to EPA and less than 1% to DHA. These are not substitutes for marine EPA+DHA and will not produce the cardiovascular or cognitive outcomes the evidence supports.

Subscribe free — one edition in your inbox every Wednesday. No spam. No conflicts of interest. Any future sponsorships will be clearly disclosed and personally vetted.

After subscribing, check your junk/spam folder for the confirmation email and mark it as ‘Not Spam’ to ensure delivery.